Amprion’s Landmark Lancet Neurology Study
A groundbreaking study published in The Lancet Neurology demonstrates the ability of a novel synuclein seed amplification assay (synSAA)...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
A groundbreaking study published in The Lancet Neurology demonstrates the ability of a novel synuclein seed amplification assay (synSAA)...
NorthStar Medical Radioisotopes and Cellectar Biosciences forged a strategic partnership which centers around the supply of non-carrier-added (n.c.a.) Actinium-225...
In a groundbreaking presentation at SCOPE Europe 2024, Susannah Finney, Clinical Operations Lead and Product Owner at Roche, UK,...
Laekna, a global biotechnology company specializing in metabolic and cancer drug development, has partnered with Eli Lilly and Company...
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and related diseases, has raised $53 million in an...
Puma Biotechnology initiated its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285). This trial investigates alisertib combined with...
COTA, Inc., a real-world data (RWD) and analytics company specializing in oncology, and Memorial Sloan Kettering Cancer Center (MSK)...
Glox Therapeutics, a company developing precision antibiotic therapies using naturally occurring bacteriocins, has received £1 million in grant funding...
Pfizer has appointed Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development,...
The National Ataxia Foundation (NAF) recently collaborated with members of Congress to conduct an informational meeting about Spinocerebellar Ataxia...